Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RCCs more than 50% cystic have good prognosis

Kashan M et al. The Journal of Urology 1 March 2018

Key clinical point: Patients with unifocal cystic renal cell carcinoma evaluated using a standardized radiologic threshold of more than 50% cystic on imaging have an excellent prognosis on both active surveillance and following surgical resection.

Major finding: Among 38 patients on active surveillance, growth rate was found to be 1.0 mm/year overall and 2.3 mm/year for the solid component. After a median follow-up of over 4 years, there was no evidence of recurrence or metastasis from cystic renal cell carcinoma.

Study details: Of the 138 cases of cystic renal cell carcinoma identified, 102 (73.9%) were renal cell carcinoma and 36 (26.1%) benign masses. Most tumors were Fuhrman grade 1-2 (77.5%), less than or equal to pT2 stage (83.4%) with clear cell histology (65.9%).

Disclosures: The authors had no relevant financial disclosures.

Source: Kashan M et al. The Journal of Urology 1 March 2018


Kashan M et al. The Journal of Urology 1 March 2018

This Week's Must Reads

Caplacizumab approved for adults with aTTP , FDA news release: FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder

IVIG versus anti-D in pediatric ITP , Lioger B et al. J Pediatr. 2019; 204:225-33.

Promising treatment for heavy menstrual bleeding , O’Brien SH et al. J Pediatr Adol Gynec. 2019 Feb 4. doi: 10.1016/j.jpag.2019.01.009.

Beware of ICH in severe hemophilia cases , Zwagemaker AF et al. EAHAD 2019, Abstract OR08.

75 exposure days is the magic number in inhibitor risk , van den Berg HM et al. EAHAD 2019, Abstract OR05.

Must Reads in Renal Cell Carcinoma

Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4

Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001

One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617